RSS Feed For (NASDAQ:MNKD)

MANNKIND (NASDAQ:MNKD)

6.88 0.06 (0.86%)
MANNKIND (NASDAQ:MNKD) Delayed :
Previous Close $6.94    52 Week High $12.30 
Open $7.12    52 Week Low $2.00 
Day High $7.24    P/E N/A 
Day Low $6.81    EPS $-2.35 
Volume 1,394,735       
More MNKD Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
ACAD 3 HOLX 3
N 3 NVO 3
WMT 3 PFE 3
HLIT 2 PEGA 2
AVCT 2 RIMM 2
SRDX 2 LF 2
View All Friends, Peers and Foes

StreetInsider Reports on MNKD by Category

View All Comments Comments on recent MNKD articles

Corey
on Nov 10, 2009
at 12:42 PM
What'd I say! You crappy ass manipulators I told you! Hapoalim is a scam and Im makin bills up urs.
Article: Hapoalim Starts MannKind (MNKD) at Sell, $1 Price Target
Elliot
on Oct 14, 2009
at 10:59 PM
Mannkind Please make sure you look back when we reach the end of January 2010 and see if you are still in business and see what the share price of MNKD is at that time
Article: Hapoalim Starts MannKind (MNKD) at Sell, $1 Price Target
corey
on Oct 14, 2009
at 03:34 PM
LOL! MNKD price target of $1?? Good luck!!!! mark my post we have hit bottom at $5.68. Hapoalim Securities just lost any credibility if they even had any.
Article: Hapoalim Starts MannKind (MNKD) at Sell, $1 Price Target
corey
on Oct 14, 2009
at 03:34 PM
LOL! MNKD price target of $1?? Good luck!!!! mark my post we have hit bottom at $5.68. Hapoalim Securities just lost any credibility if they even had any.
Article: Hapoalim Starts MannKind (MNKD) at Sell, $1 Price Target
Tony M
on May 18, 2008
at 11:44 AM
MannKind (MNKD) Sees Upside Action Now with no other competition, and a drug that could be a revolutionary, I think the risk reward ratio is very solid.
Article: MannKind (MNKD) Sees Upside Action
View All Comments

Comments on MNKD

Alfred McBride
at Nov 7, 2009 05:36 PM
Afresa May Stop Progression of Diabetes Type II and Prediabetes! Al Mann Mentioned that the Experts told him that Afresa might stop the progression of Diabetes! In Type II and pre-diabetes! This opens up a larger market based only on studies at this time and larger clinical trials peer reviewed will have to take place..but.. they also noted Zero Hypo's when Afresa was used Alone at a Zero Carb diet!! ZERO IN ALL CASES!!